Literature DB >> 11093955

IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease.

J B Pucilowska1, K K McNaughton, N K Mohapatra, E C Hoyt, E M Zimmermann, R B Sartor, P K Lund.   

Abstract

This study tested the hypothesis that insulin-like growth factor I (IGF-I) expression is increased at sites of fibrosis in diseased intestine of patients with Crohn's disease (CD). IGF-I mRNA was quantified by RNase protection assay in uninvolved and involved intestine of 13 CD patients (10 ileum, 3 colon) and 7 ulcerative colitis (UC) patients (colon). In situ hybridization histochemistry compared the localization of IGF-I and procollagen alpha1(I) mRNAs. Masson's trichrome staining and immunohistochemistry for IGF-I precursor, alpha-smooth muscle actin (A), vimentin (V), desmin (D), and c-kit were used to examine the mesenchymal cell subtypes that express IGF-I and collagen in uninvolved and involved ileum and colon of CD patients and "normal" ileum and colon from noninflammatory controls. IGF-I mRNA was elevated in involved ileum and colon of patients with CD but not in involved colon of patients with UC. IGF-I and procollagen alpha1(I) mRNA showed overlapping distribution within fibrotic submucosa and muscularis propria of involved CD ileum and colon. In involved CD intestine, increased IGF-I precursor expression localized to mesenchymal cells in regions of tissue disorganization and fibrosis in muscularis mucosa, submucosa, and muscularis propria. In these regions, there were increased numbers of V(+) cells relative to normal or uninvolved intestine. Increased IGF-I expression was localized to cells with a phenotype typical of fibroblasts (V(+)/A(-)/D(-)), myofibroblasts (V(+)/A(+)/D(+)), and, to a lesser extent, cells with normal enteric smooth muscle phenotype (V(-)/A(+)/D(+)). We conclude that increased IGF-I expression in multiple mesenchymal cell subtypes and increased numbers of cells with fibroblast/myofibroblast phenotype are involved in fibrosis associated with CD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093955     DOI: 10.1152/ajpgi.2000.279.6.G1307

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  38 in total

Review 1.  Therapeutic application of stem cells in gastroenterology: an up-date.

Authors:  Patrizia Burra; Debora Bizzaro; Rachele Ciccocioppo; Fabio Marra; Anna Chiara Piscaglia; Laura Porretti; Antonio Gasbarrini; Francesco Paolo Russo
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

2.  Phenotypic change and accumulation of smooth muscle cells in strictures in Crohn's disease: relevance to local angiotensin II system.

Authors:  Takehisa Suekane; Yoshihiro Ikura; Kenji Watanabe; Junko Arimoto; Yoko Iwasa; Yoshimi Sugama; Soichiro Kayo; Kenichi Sugioka; Takahiko Naruko; Kiyoshi Maeda; Kosei Hirakawa; Tetsuo Arakawa; Makiko Ueda
Journal:  J Gastroenterol       Date:  2010-04-02       Impact factor: 7.527

3.  Altered expression of type I insulin-like growth factor receptor in Crohn's disease.

Authors:  F El Yafi; R Winkler; P Delvenne; N Boussif; J Belaiche; E Louis
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 4.  Colonic subepithelial myofibroblasts in mucosal inflammation and repair: contribution of bone marrow-derived stem cells to the gut regenerative response.

Authors:  Akira Andoh; Shigeki Bamba; Yoshihide Fujiyama; Mairi Brittan; Nicholas A Wright
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

Review 5.  Wound healing and fibrosis in intestinal disease.

Authors:  F Rieder; J Brenmoehl; S Leeb; J Schölmerich; G Rogler
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

6.  Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling.

Authors:  Jurgen J W Mulsow; R William G Watson; John M Fitzpatrick; P Ronan O'Connell
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

Review 7.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

8.  Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis.

Authors:  Dimitrios C Ziogas; Beatriz Gras-Miralles; Sarah Mustafa; Brenda M Geiger; Robert M Najarian; Jutta M Nagel; Sarah N Flier; Yury Popov; Yu-Hua Tseng; Efi Kokkotou
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-28       Impact factor: 4.052

9.  Intestinal subepithelial myofibroblasts in inflammatory bowel diseases.

Authors:  Akira Andoh; Sanae Fujino; Takafumi Okuno; Yoshihide Fujiyama; Tadao Bamba
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

10.  Anti-TNFα alters the natural history of experimental Crohn's disease in rats when begun early, but not late, in disease.

Authors:  Phyllissa Schmiedlin-Ren; Laura J Reingold; Christopher S Broxson; Ahren C Rittershaus; Josh S Brudi; Jeremy Adler; Scott R Owens; Ellen M Zimmermann
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-08-25       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.